The cost-effectiveness of the cytology laboratory and new cytology technologies in cervical cancer prevention.
Am J Clin Pathol
; 111(2): 259-66, 1999 Feb.
Article
en En
| MEDLINE
| ID: mdl-9930150
The effect of changes in cytology laboratory costs, including the costs of new technologies, on the cost-effectiveness of cervical cancer prevention has not been studied. Using University of Iowa laboratory detection rates and costs, a decision model determined the cost-effectiveness of the laboratory with and without new technologies. Compared with not performing a cervicovaginal smear, the cost to increase the discounted life expectancy per patient by 1 year was $2,805 for the laboratory component alone and $19,655 for the entire cervical cancer prevention strategy. In moderate- to high-risk women, cervical cancer screening was cost-effective even at high cytology laboratory costs (eg, $75 per smear). New technologies were cost-effective only if they resulted in a substantial increase in the detection of high-grade squamous intraepithelial lesions (eg, an additional 236 high-grade squamous intraepithelial lesions per 10,000 women). New technologies have not demonstrated these increased detection rates.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Frotis Vaginal
/
Neoplasias del Cuello Uterino
/
Tamizaje Masivo
/
Laboratorios
Tipo de estudio:
Health_economic_evaluation
/
Prognostic_studies
/
Screening_studies
Aspecto:
Patient_preference
Límite:
Female
/
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Am J Clin Pathol
Año:
1999
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Reino Unido